G J Moyle - JoVE Visualize

Showing results (21-30 of 33) with videos related to

Pageof 4

Sort By:

HIV Medicine|May 7, 2005

Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsulesS D Portsmouth, J Osorio, K McCormick, et al.

AIDS (London, England)|August 16, 2001

Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapyG J Moyle, M Lloyd, B Reynolds, et al.

HIV Medicine|July 18, 2008

Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapyD Maitland, A Jackson, J Osorio, et al.

Clinical and Experimental Immunology|May 25, 2013

Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapyA A Herasimtschuk, B R Hansen, A Langkilde, et al.

Antiviral Therapy|May 1, 2001

Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing CommitteeG J Moyle, E Bouza, F Antunes, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|October 3, 2000

Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapyG V Matthews, G J Moyle, S Mandalia, et al.

British Journal of Clinical Pharmacology|September 5, 2002

Interaction between saquinavir soft-gel and rifabutin in patients infected with HIVG J Moyle, N E Buss, T Goggin, et al.

HIV Clinical Trials|October 9, 2001

Efficacy of a nelfinavir- and nevirapine-containing salvage regimenA K Sullivan, M R Nelson, A Shaw, et al.

Journal of Clinical Pharmacology|September 2, 1998

Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virusG J Moyle, M Youle, C Higgs, et al.

HIV Medicine|March 12, 2004

A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infectionG J Moyle, L Lysakova, S Brown, et al.

Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:

Pageof 4

HIV Medicine|May 7, 2005

Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsulesS D Portsmouth, J Osorio, K McCormick, et al.

AIDS (London, England)|August 16, 2001

Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapyG J Moyle, M Lloyd, B Reynolds, et al.

HIV Medicine|July 18, 2008

Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapyD Maitland, A Jackson, J Osorio, et al.

Clinical and Experimental Immunology|May 25, 2013

Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapyA A Herasimtschuk, B R Hansen, A Langkilde, et al.

Antiviral Therapy|May 1, 2001

Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing CommitteeG J Moyle, E Bouza, F Antunes, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|October 3, 2000

Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapyG V Matthews, G J Moyle, S Mandalia, et al.

British Journal of Clinical Pharmacology|September 5, 2002

Interaction between saquinavir soft-gel and rifabutin in patients infected with HIVG J Moyle, N E Buss, T Goggin, et al.

HIV Clinical Trials|October 9, 2001

Efficacy of a nelfinavir- and nevirapine-containing salvage regimenA K Sullivan, M R Nelson, A Shaw, et al.

Journal of Clinical Pharmacology|September 2, 1998

Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virusG J Moyle, M Youle, C Higgs, et al.

HIV Medicine|March 12, 2004

A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infectionG J Moyle, L Lysakova, S Brown, et al.

Pageof 4